Updated Jul 16, 2026
REED ELIZABETH E has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $5.03M.
Elizabeth E. Reed serves as the Chief Legal Officer and General Counsel at Travere Therapeutics, Inc., a biopharmaceutical company focused on therapies for rare kidney, liver, and metabolic diseases. She has been involved in the company's legal affairs and compliance matters.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 2.1K | $43.95 | $91K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 2.2K | $46.65 | $101K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 4.2K | $0.00 | |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 20.0K | $45.00 | $900K |
| 2026-05-07 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 20.0K | $17.96 | $359K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 1.6K | $42.53 | $66K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 5.2K | $41.62 | $218K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 7.2K | $41.93 | $303K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale | 37.5K | $41.07 | $1.54M |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 7.5K | $15.46 | $116K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 20.0K | $17.96 | $359K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | M — Option exercise | 10.0K | $19.08 | $191K |
| 2026-04-16 | TVTX | Travere Therapeutics, Inc. | A — Grant or award | 14.0K | $0.00 | |
| 2026-04-02 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 10.0K | $30.00 | $300K |
| 2026-04-02 | TVTX | Travere Therapeutics, Inc. | M — Option exercise [10b5-1] | 10.0K | $15.46 | $155K |
| 2026-03-18 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 10.0K | $28.09 | $281K |
| 2026-03-18 | TVTX | Travere Therapeutics, Inc. | M — Option exercise [10b5-1] | 10.0K | $19.08 | $191K |
| 2026-02-19 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 4.3K | $28.26 | $122K |
| 2026-02-19 | TVTX | Travere Therapeutics, Inc. | S — Open-market sale [10b5-1] | 5.7K | $27.50 | $156K |
| 2026-02-19 | TVTX | Travere Therapeutics, Inc. | M — Option exercise [10b5-1] | 10.0K | $19.08 | $191K |
Elizabeth E. Reed serves as the Chief Legal Officer and General Counsel at Travere Therapeutics, Inc., a biopharmaceutical company focused on therapies for rare kidney, liver, and metabolic diseases. She has been involved in the company's legal affairs and compliance matters.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 17 open-market sales ($5.03M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live REED ELIZABETH E profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.